Vertex Pharmaceuticals is prepping for its Q1 earnings reveal on May 5, with analysts expecting mixed results. EPS is ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, 90 mg and tentative ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

Analysts anticipate Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.31. Anticipation surrounds Vertex Pharmaceuticals's announcement, with investors hoping to hear about both ...

VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...

Vertex Pharmaceuticals is gearing up to drop its earnings on May 5, and the market’s popcorn is already popped. The company’s ...

The stock's fall snapped a seven-day winning streak.

"It is not some Disney story of just triumph and resilience, it was really hard," Smith tells PEOPLE about his recovery ...

The Davenport Core Leaders Fund declined 3.48% in Q1 2025, although it did exceed its benchmark. Click here to read the full ...

CRISPR Therapeutics' revenue streams currently rely heavily on grants and collaboration revenues from its partnership with Vertex Pharmaceuticals (VRTX). The collaboration has yielded Casgevy, a ...

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...